Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cross

Showing results (491-500 of 595) with videos related to

Pageof 60
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III studyP Kirkbride, A Bezjak, J Pater, et al.
Haematologica|May 30, 2013
Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasmsCristina Pérez, Marien Pascual, José Ignacio Martín-Subero, et al.
Leukemia|November 13, 2008
BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting featuresN C P Cross, G Q Daley, A R Green, et al.
Leukemia|August 13, 2010
Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formationJ Score, M J Calasanz, O Ottman, et al.
Leukemia|December 22, 2018
PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasiaAndrew Chase, Andrea Pellagatti, Shalini Singh, et al.
Nature Communications|January 10, 2015
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromesMoritz Gerstung, Andrea Pellagatti, Luca Malcovati, et al.
Leukemia|October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosisM Jawhar, J Schwaab, S Schnittger, et al.
Clinical Chemistry|March 9, 2013
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scaleHelen E White, John Hedges, Israel Bendit, et al.
British Journal of Haematology|January 25, 2003
Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disordersE Joanna Baxter, Shashikant Kulkarni, José-Luis Vizmanos, et al.
British Journal of Haematology|December 4, 2025
Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology GuidelineAnna L Godfrey, Alesia A Khan, Andrew McGregor, et al.
Pageof 60

Showing results (491-500 of 595) with videos related to

Sort By:
Pageof 60
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III studyP Kirkbride, A Bezjak, J Pater, et al.
Haematologica|May 30, 2013
Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasmsCristina Pérez, Marien Pascual, José Ignacio Martín-Subero, et al.
Leukemia|November 13, 2008
BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting featuresN C P Cross, G Q Daley, A R Green, et al.
Leukemia|August 13, 2010
Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formationJ Score, M J Calasanz, O Ottman, et al.
Leukemia|December 22, 2018
PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasiaAndrew Chase, Andrea Pellagatti, Shalini Singh, et al.
Nature Communications|January 10, 2015
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromesMoritz Gerstung, Andrea Pellagatti, Luca Malcovati, et al.
Leukemia|October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosisM Jawhar, J Schwaab, S Schnittger, et al.
Clinical Chemistry|March 9, 2013
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scaleHelen E White, John Hedges, Israel Bendit, et al.
British Journal of Haematology|January 25, 2003
Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disordersE Joanna Baxter, Shashikant Kulkarni, José-Luis Vizmanos, et al.
British Journal of Haematology|December 4, 2025
Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology GuidelineAnna L Godfrey, Alesia A Khan, Andrew McGregor, et al.
Pageof 60